QGEN
HealthcareQiagen N.V.
$46.49
+$1.30 (+2.88%)
Jan 5, 2026
Price History (1Y)
Analysis
Qiagen N.V. is a healthcare company operating in the diagnostics and research industry. With a market capitalization of $10.08B, it has a substantial scale, employing 5700 individuals. The company's revenue has been $2.07B (TTM), indicating its significant presence in the sector. The financial health of Qiagen N.V. is reflected in its profitability metrics. The company boasts gross margins of 80.3%, operating margins of 25.8%, and a profit margin of 19.6%. Its returns on equity and assets are 11.3% and 8.2%, respectively, indicating its ability to generate income from shareholders' investments. On the balance sheet side, Qiagen N.V. has $1.69B in cash and $2.16B in debt, resulting in a debt-to-equity ratio of 59.09. The valuation context for Qiagen N.V. is characterized by a price-to-earnings (TTM) ratio of 24.34, with forward P/E at 18.29. The company has achieved revenue growth of 6.1% year-over-year and earnings growth of 32.5%. Additionally, the dividend yield stands at 55.0%, with a payout ratio of 13.5%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Visit website →Key Statistics
- Market Cap
- $10.08B
- P/E Ratio
- 24.34
- 52-Week High
- $51.88
- 52-Week Low
- $37.63
- Avg Volume
- 1.16M
- Beta
- 0.66
- Dividend Yield
- 55.00%
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NYQ
- Country
- Netherlands
- Employees
- 5,700